HOME
|
CONTACT
|
SITE MAP
|
Search
ABOUT HGS
MANAGEMENT
BOARD OF DIRECTORS
RESEARCH & DEVELOPMENT
> Human Antibody Technology
> Albumin-Fusion Technology
> Drug Development at HGS
MANUFACTURING
HGS EUROPE
CALENDAR OF EVENTS
INTERNET PRIVACY POLICY
LEGAL NOTICES
GRANTS AND RESEARCH
CONTACTS
PIPELINE
BENLYSTA
Raxibacumab
Mapatumumab
GSK Products
CONTACTS
PARTNERS
LEAD COMMERCIAL COLLABORATIONS
PRODUCT COLLABORATIONS
TECHNOLOGY COLLABORATIONS
CONTACTS
INVESTORS
CORPORATE GOVERNANCE
STOCK INFORMATION
CALENDAR OF EVENTS
ANNUAL MEETING
CORPORATE PRESENTATION
ANNUAL REPORTS
QUARTERLY RESULTS
SEC FILINGS
INSIDER TRANSACTIONS
ANALYST COVERAGE
E-MAIL ALERTS
INVESTOR RELATIONS CONTACT
NEWS
NEWS RELEASES
CALENDAR OF EVENTS
EMAIL ALERTS
MEDIA CONTACT
CAREERS
SEARCH FOR JOBS
Guidelines to Apply
WORK & LIFE AT HGS
DIVERSITY
BENEFITS
RECRUITER INFORMATION
INVESTORS
CORPORATE GOVERNANCE
STOCK INFORMATION
CALENDAR OF EVENTS
ANNUAL MEETING
CORPORATE PRESENTATION
ANNUAL REPORTS
QUARTERLY RESULTS
SEC FILINGS
INSIDER TRANSACTIONS
ANALYST COVERAGE
EMAIL ALERTS
INVESTOR RELATIONS CONTACT
SEC Filings
SEC Filing Keyword Search
(
View search tips
)
Groupings Filter
(
View SEC Groupings descriptions
)
All Forms
3,4,5
Annual Filings
Current Reports
Mergers & Acquisitions
Other
Proxy Filings
Quarterly Filings
Registration Statements
View Section 16 Filings (3,4,5)
<< First
| Previous
|
Next
|
Last
>>
Filing Date
Form
Description
Filing Group
Downloads
02/14/13
SC 13G/A
An amendment to the SC 13G filing
Other
02/13/13
SC 13G/A
An amendment to the SC 13G filing
Other
09/10/12
SC 13G/A
An amendment to the SC 13G filing
Other
08/17/12
4/A
Amendment to a previously filed 4
3,4,5
08/13/12
15-12B
Termination of registration under Section 12(g) or suspension of duty to file reports
Other
08/10/12
EFFECT
EFFECT
Other
08/10/12
SC 13G/A
An amendment to the SC 13G filing
Other
08/09/12
CT ORDER
CT ORDER
Other
08/09/12
3
Initial filing by director officer or owner of more than ten percent.
3,4,5
08/09/12
3
Initial filing by director officer or owner of more than ten percent.
3,4,5
<< First
| Previous
|
Next
|
Last
>>
[ Back ]
